Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer

doi:10.3748/wjg.v17.i43.4779

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5298)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

474

HTML

4513

Figures (1-3)

166

Tables (1-6)

145

Sum=5298

Nov 21, 2011 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (55)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Nov 21, 2011; 17(43): 4779-4786
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779

Full Size Figure Download Figure

Figure 3 Progression-free survival of advanced colorectal cancer patients with KRAS wild type and patients with KRAS mutation treated by cetuximab-containing chemotherapy. Thirty-seven of 45 patients were successfully tested KRAS gene in cetuximab-containing chemotherapy group, the median PFS of patients with KRAS wild type was significantly higher than that of patients with KRAS mutation ( 5.0 mo and 2.5 mo, respectively, P = 0.02). PFS: Progression-free survival.

Citation: Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Chen XX, Wang F, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol 2011; 17(43): 4779-4786
URL: https://www.wjgnet.com/1007-9327/full/v17/i43/4779.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i43.4779